Results 61 to 70 of about 472,072 (313)

Melatonin attenuates cholestatic liver injury by improving bile acid metabolism in mice

open access: yes陆军军医大学学报
Objective To explore the mechanism of melatonin (Mel) alleviating cholestatic liver injury in a mouse cholestasis model induced by cholic acid (CA) feeding.
ZHANG Hongjia, TAN Ya, ZHAO Nan
doaj   +1 more source

Fighting the fatty liver [PDF]

open access: yesNature, 2017
Increased levels of obesity are driving an epidemic of non-alcoholic fatty liver disease. Understanding, diagnosing and treating this progressive condition are now priorities.
openaire   +2 more sources

Nonalcoholic Fatty Liver Disease [PDF]

open access: yesCanadian Journal of Gastroenterology and Hepatology, 2018
According to the papers published in this special issue, NAFLD is a serious problem, which each author from their own aspect tried to clarify. Regarding the fact that NAFLD is rarely isolated and that it is correlated with obesity, diabetes type 2, polycystic ovarian syndrome, obstructive sleep apnea, and some cognitive deficits, its pathophysiology ...
Branka Filipović   +3 more
openaire   +5 more sources

Excess portal venous long-chain fatty acids induce syndrome X via HPA axis and sympathetic activation [PDF]

open access: yes, 2000
We tested the hypothesis that excessive portal venous supply of long-chain fatty acids to the liver contributes to the development of insulin resistance via activation of the hypothalamus-pituitary-adrenal axis (HPA axis) and sympathetic system.
Scheurink, AJW   +16 more
core  

Linking neurogenesis, oligodendrogenesis, and myelination defects to neurodevelopmental disruption in primary mitochondrial disorders

open access: yesFEBS Letters, EarlyView.
Mitochondrial remodeling shapes neural and glial lineage progression by matching metabolic supply with demand. Elevated OXPHOS supports differentiation and myelin formation, while myelin compaction lowers mitochondrial dependence, revealing mitochondria as key drivers of developmental energy adaptation.
Sahitya Ranjan Biswas   +3 more
wiley   +1 more source

Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes

open access: yes, 2013
BackgroundThe relationship between non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) in type 2 diabetes is currently unknown. We examined the relationship between NAFLD and risk of incident AF in people with type 2 diabetes.Methods ...
Zoppini Giacomo   +39 more
core   +1 more source

The human gut microbiome across the life course

open access: yesFEBS Letters, EarlyView.
Despite significant individual variation and continuous change throughout life, the human gut microbiome follows some life stage‐specific trends. This article provides a brief overview of how gut microbiome composition shifts across different phases of life. Created in BioRender. Özkurt, E. (2026) https://BioRender.com/8q4nrnc.
Alise J. Ponsero   +4 more
wiley   +1 more source

Development of a tryptophan metabolomics-based diagnostic model for hepatic encephalopathy in liver cirrhosis

open access: yesEuropean Journal of Medical Research
Background Tryptophan (TRP) metabolism is implicated in the pathogenesis of hepatic encephalopathy (HE). Abnormal TRP metabolites correlate with HE severity and may represent potential biomarkers. This study employed targeted metabolomics to characterize
Xiao Cao   +4 more
doaj   +1 more source

Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials

open access: yesBMJ Open, 2021
Objective To give a comprehensive efficacy and safety ranking of different therapeutic regimens of ranibizumab for neovascular age-related macular degeneration (nAMD).Design A systematic review and network meta-analysis.Methods The PubMed, Embase ...
Youxin Chen, Xinyu Zhao, Lihui Meng
doaj   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy